



# Resource impact statement

Resource impact

Published: 20 October 2021

[www.nice.org.uk](http://www.nice.org.uk)

## No significant resource impact is anticipated

NICE has recommended berotralstat as an option for preventing recurrent attacks of hereditary angioedema in people 12 years and older, only if:

- they have a least 2 attacks per month and
- it is stopped if the number of attacks per month does not reduce by at least 50% after 3 months.

It is only recommended if the company provides berotralstat according to the commercial arrangement.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the population size is small (the number of people eligible for treatment with berotralstat each year is less than 300). The cost of treatment with berolralstat is expected to be mitigated by the reduction in recurrent attacks of hereditary angioedema and its associated cost of treatment.

Berotralstat has a discount that is commercial in confidence. For enquiries about the patient access scheme, please contact [enquiries@biocryst.co.uk](mailto:enquiries@biocryst.co.uk) for details.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.